Market cap
$12,941 Mln
Market cap
$12,941 Mln
Revenue (TTM)
$1,404 Mln
P/E Ratio
73
P/B Ratio
9.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$130 Mln
ROE
0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
56.3
Debt to Equity
0.2
Book Value
$36.2
EPS
$4.5
Face value
--
Shares outstanding
39,243,053
CFO
$44.61 Mln
EBITDA
$247.81 Mln
Net Profit
$151.46 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Penumbra (PEN)
| 7.3 | -0.7 | -6.8 | 23.2 | 6.0 | 3.3 | 19.9 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Penumbra (PEN)
| 30.9 | -5.5 | 13.1 | -22.6 | 64.2 | 6.5 | 34.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Penumbra (PEN)
|
333.5 | 12,941.2 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73 | 9.1 |
| 8.4 | 5,633.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 277.0 | 7,476.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 9.9 | 1.0 | |
| 39.6 | 6,195.5 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.4 | |
| 27.5 | 4,414.8 | 2,719.5 | 47.0 | 8.4 | 1.6 | 96.2 | 1.4 | |
| 122.9 | 6,939.8 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.6 | |
| 82.1 | 5,456.9 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.6 | 5.0 | |
| 178.4 | 9,341.0 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.6 | 12.9 | |
| 130.6 | 7,400.2 | 738.3 | 48.9 | 11.4 | 2.4 | 150.8 | 3.5 | |
| 32.7 | 14,139.4 | 6,178.4 | 626.5 | 13.0 | 11.9 | 23.2 | 2.6 |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the... Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California. Address: One Penumbra Place, Alameda, CA, United States, 94502 Read more
Co-Founder, Chairman, President & CEO
Mr. Adam Elsesser
Co-Founder & Director
Dr. Arani Bose M.D.
Headquarters
Alameda, CA
Website
The share price of Penumbra Inc (PEN) is $333.50 (NYSE) as of 22-Apr-2026 10:45 EDT. Penumbra Inc (PEN) has given a return of 6.01% in the last 3 years.
The P/E ratio of Penumbra Inc (PEN) is 72.96 times as on 13-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
68.93
|
8.58
|
|
2024
|
665.53
|
8.10
|
|
2023
|
108.66
|
8.38
|
|
2022
|
-4,322.18
|
8.66
|
|
2021
|
4,102.34
|
11.28
|
The 52-week high and low of Penumbra Inc (PEN) are Rs 362.41 and Rs 221.26 as of 22-Apr-2026.
Penumbra Inc (PEN) has a market capitalisation of $ 12,941 Mln as on 13-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Penumbra Inc (PEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.